2-(3-hydroxy-1,2-oxazol-5-yl)acetic acid | 54489-27-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-hydroxy-1,2-oxazol-5-yl)acetic acid
• 英文别名: 2-(3-Hydroxyisoxazol-5-yl)acetic acid；3-Hydroxyisoxazol-5-ylacetic acid；2-(3-oxo-1,2-oxazol-5-yl)acetic acid
• CAS: 54489-27-9
• 化学式: C₅H₅NO₄
• mdl: MFCD19229173
• 分子量: 143.099
• InChiKey: WPMUQANSUHHDJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(3-hydroxy-1,2-oxazol-5-yl)acetic acid 在 溶剂黄146 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 乙醇 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 (1R)-6-ethoxy-N-(7-fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)-2-((3-hydroxy-1,2-oxazol-5-yl)acetyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamide
  参考文献：
  名称：

  TW2016/2105

  摘要：

  公开号：
• 作为产物：
  描述：

  二氧化碳 、 lithium ((3-oxidoisoxazol-5-yl)methyl)lithium 以 四氢呋喃 为溶剂， 反应 4.0h， 以51%的产率得到2-(3-hydroxy-1,2-oxazol-5-yl)acetic acid
  参考文献：
  名称：

  Generation and reactions of the dianion of 3-hydroxy-5-methylisoxazole, a convenient .beta.-oxo amide synthon. Total synthesis of muscimol

  摘要：

  DOI：

  10.1021/jo00171a030

文献信息

• Derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene active on the
  申请人：Zambon Group, S.P.A.

  公开号：US05747513A1

  公开（公告）日：1998-05-05

  Compounds of the formula: ##STR1## wherein R is a hydrogen atom or an OY group; R.sub.1 is a hydrogen atom or in OY' group; R.sub.2 is a hydrogen atom or an OY" group; provided that at lent one among R, R.sub.1 and R.sub.2 is hydrogen but R, R.sub.1, and R.sub.2 are not contemporaneously hydrogen atoms and R.sub.1 and R.sub.2 are not contemporaneously OY' or OY" groups respectively; m is an integer 1 or 2; n is an integer 3 to 8; p is an integer 2, 3, or 4; R.sub.3 is a hydrogen atom or a C.sub.1 -C.sub.4 alkyl; R.sub.4 is a phenyl optionally substituted by halogen atom or a C.sub.1 -C.sub.3 alkyl or alkoxy group or a 5- or 6- membered heteroaryl containing one or more heteroatoms selected from oxygen, nitrogen and sulphur, optionally substituted by halogen atoms, hydroxy groups, C.sub.1 -C.sub.3 alkyl or alkoxy groups; X is CH.sub.2, NH, S, SO, SO.sub.2, CO, CF.sub.2, O and, when R.sub.4 is a 5- or 6- membered heteroaryl, X can be also a single bond. Pharmaceutically acceptable salts are described. The compounds of formula (I) are useful in the treatment of arterial hypertension and heart failure, of renal insufficiency, of peripheral arteriopathies and of cerebrovascular insufficiencies.

  该公式化合物为：##STR1## 其中R为氢原子或OY基团；R.sub.1为氢原子或OY'基团；R.sub.2为氢原子或OY"基团；但要求R、R.sub.1和R.sub.2中至少有一个是氢，且R、R.sub.1和R.sub.2不同时为氢原子，且R.sub.1和R.sub.2不同时为OY'或OY"基团；m为整数1或2；n为整数3至8；p为整数2、3或4；R.sub.3为氢原子或C.sub.1-C.sub.4烷基；R.sub.4为苯环，可选择地被卤素原子或C.sub.1-C.sub.3烷基或烷氧基取代，或含有氧、氮和硫等一种或多种杂原子的5-或6-成员杂环芳基，可选择地被卤素原子、羟基、C.sub.1-C.sub.3烷基或烷氧基取代；X为CH.sub.2、NH、S、SO、SO.sub.2、CO、CF.sub.2、O，当R.sub.4为5-或6-成员杂环芳基时，X也可以是一个单键。描述了药用可接受的盐。公式(I)的化合物在治疗动脉高压和心力衰竭、肾功能不全、周围动脉病和脑血管功能不全方面是有用的。
• 7.alpha.-Methoxycephalosporin derivatives and their pharmaceutical
  申请人：Sankyo Company Limited

  公开号：US04247548A1

  公开（公告）日：1981-01-27

  7.alpha.-Methoxycephalosporin derivatives of general formula (I): ##STR1## wherein: R.sup.1 represents a hydroxy group; a C.sub.1 -C.sub.4 alkoxy group; a C.sub.2 -C.sub.5 aliphatic acyloxy group; a benzoyloxy group which is unsubstituted or has one or more C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, nitro or halogen substituents; a benzenesulphonyloxy group which is unsubstituted or has one or more C.sub.1 -C.sub.4 alkyl substituents; or a C.sub.1 -C.sub.3 alkanesulphonyloxy group which is unsubstituted or has one or more C.sub.1 -C.sub.3 alkoxy, cyano, nitro, halogen or C.sub.2 -C.sub.4 alkoxycarbonyl substituents; R.sup.2 represents a hydrogen atom, a C.sub.1 -C.sub.4 alkyl group, a halogen atom, a carboxyl group, a C.sub.2 -C.sub.5 alkoxycarbonyl group, a carbamoyl group, an alkylcarbamoyl group in which the alkyl moiety has from 1 to 3 carbon atoms, a di(C.sub.1 -C.sub.3 alkyl)carbamoyl group or a cyano group; R.sup.3 represents a hydrogen atom; an acetoxy group; a carbamoyloxy group; or a tetrazolylthio, thiadiazolylthio or oxadiazolylthio group which is unsubstituted or has one or more C.sub.1 -C.sub.3 alkyl, sulphomethyl or di(C.sub.1 or C.sub.2 alkyl)amino(C.sub.1 -C.sub.3 alkyl) substituents; m is 0 or 1; and n is 0 or 2 exhibit potent antibacterial activity and are thus useful as medicines. The derivatives can be prepared by reacting the corresponding 7.alpha.-methoxycephalosporin derivative having an amino group at the 7.beta.-position with an acid halide corresponding to the substituted acetyl group which it is desired to attach to the amino group at the 7.beta.-position or by reacting Cephamycin C with the same acid halide.

  7.alpha.-甲氧基头孢菌素衍生物的一般式(I)：##STR1## 其中：R.sup.1代表羟基；C.sub.1-C.sub.4烷氧基；C.sub.2-C.sub.5脂肪酰氧基；苯甲酰氧基，未取代或具有一个或多个C.sub.1-C.sub.4烷基，C.sub.1-C.sub.4烷氧基，硝基或卤素取代基；苯磺酰氧基，未取代或具有一个或多个C.sub.1-C.sub.4烷基取代基；或C.sub.1-C.sub.3烷基磺酰氧基，未取代或具有一个或多个C.sub.1-C.sub.3烷氧基，氰基，硝基，卤素或C.sub.2-C.sub.4烷氧羰基取代基；R.sup.2代表氢原子，C.sub.1-C.sub.4烷基，卤素原子，羧基，C.sub.2-C.sub.5烷氧羰基，氨基甲酰基，烷基氨基甲酰基，其中烷基部分具有1至3个碳原子，二(C.sub.1-C.sub.3烷基)氨基甲酰基或氰基；R.sup.3代表氢原子；乙酰氧基；氨基甲酰氧基；或未取代或具有一个或多个C.sub.1-C.sub.3烷基，磺甲基或二(C.sub.1或C.sub.2烷基)氨基(C.sub.1-C.sub.3烷基)取代基的四唑硫基，噻二唑硫基或噁二唑硫基；m为0或1；n为0或2。这些衍生物具有强效的抗菌活性，因此可用作药物。可以通过将在7.beta.-位置具有氨基的相应7.alpha.-甲氧基头孢菌素衍生物与所需附加到7.beta.-位置氨基的取代乙酰基对应的酸卤反应，或通过将头霉素C与相同的酸卤反应来制备这些衍生物。
• EP3239143
  申请人：——

  公开号：——

  公开（公告）日：——
• EP3018123
  申请人：——

  公开号：——

  公开（公告）日：——
• Rationally designed "dipeptoid" analogs of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist (CI-988)
  作者：Martin J. Drysdale、Martyn C. Pritchard、David C. Horwell

  DOI：10.1021/jm00092a007

  日期：1992.7

  This paper outlines the synthesis of selected acid mimics of the non-peptide CCK-B selective antagonist CI-988, 1. CCK-B and CCK-A binding affinities of these analogues are described and their CCK-B affinity and selectivity rationalized by consideration of the pK(a) values, charge distribution, and geometry of the respective acid mimics. Several of the compounds have CCK-B binding affinities similar to the parent carboxylic acid 1 (CCK-B, IC50 = 1.7 nM; pK(a) = 5.6) and span a pK(a) range of <1 (sulfonic acid 27) to >9.5 (5-thio-1,2,4-triazole 24). Among the more active compounds synthesized are tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[2-[[2-[[(3-hydroxy-5-isoxazolyl)acetyl]-amino]-2-phenylethyl]amino]-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl]carbamate (15), tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[2-[(1-oxo-3-sulfopropyl)amino]-2-phenylethyl]amino]-ethyl]carbamate, monosodium salt (27), and tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[2-1[(1H-1,2,4-triazol-5-ylsulfinyl)acetyl]amino]-2-phenylethyl]amino]ethyl]carbamic acid (34) which have CCK-B binding affinities of IC50 = 2.6,1.3, and 1.7 nM, CCK-A/-B ratios of 650,780, and 550 and pK(a) values of 6.5, <1, and 7.0, respectively.